Selumetinib

Brand names: Koselugo · Active ingredient: Selumetinib

In short: KOSELUGO is indicated for the treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN) .

Forms & strengthsCapsules: •10 mg selumetinib: white to off-white, opaque, hard capsule sealed with a clear band and marked with “SEL 10” in black ink. •25 mg selumetinib: blue, opaque, hard capsule sealed with a clear band and marked with “SEL 25” in black ink. …
LabelAstraZeneca Pharmaceuticals LP
Label updatedJun 01, 2026

What is Selumetinib used for?

KOSELUGO is indicated for the treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN) .

Selumetinib dosage

The recommended dosage of KOSELUGO capsules and KOSELUGO oral granules for adult and pediatric patients 1 year of age and older, based on body surface area, is 25 mg/m2 orally twice daily, until disease progression or unacceptable toxicity .

Body Surface Area

The recommended dosage of KOSELUGO capsules for patients with a BSA less than 0.55 m2 has not been established. | KOSELUGO Capsules

0.55 – 0.69 m2 | 20 mg in the morning and 10 mg in the evening

0.70 – 0.89 m2 | 20 mg twice daily

0.90 – 1.09 m2 | 25 mg twice daily

1.10 – 1.29 m2 | 30 mg twice daily

1.30 – 1.49 m2 | 35 mg twice daily

1.50 – 1.69 m2 | 40 mg twice daily

1.70 – 1.89 m2 | 45 mg twice daily

≥ 1.90 m2 | 50 mg twice daily

Body Surface Area

The recommended dosage of KOSELUGO oral granules for patients with a BSA less than 0.40 m2 has not been established. | KOSELUGO Oral Granules

0.40 – 0.59 m2 | 12.5 mg twice daily

0.60 – 0.69 m2 | 15 mg twice daily

0.70 – 0.89 m2 | 20 mg twice daily

0.90 – 1.09 m2 | 25 mg twice daily

1.10 – 1.29 m2 | 30 mg twice daily

1.30 – 1.49 m2 | 35 mg twice daily

1.50 – 1.69 m2 | 40 mg twice daily

1.70 – 1.89 m2 | 45 mg twice daily

≥ 1.90 m2 | 50 mg twice daily

KOSELUGO is available in two dosage forms: KOSELUGO capsules and KOSELUGO oral granules. Prescribe KOSELUGO oral granules for patients who have difficulty swallowing whole capsules.

KOSELUGO Capsules

•

Administer KOSELUGO capsules to patients who can swallow a whole capsule.

•

Swallow KOSELUGO capsules whole. Do not open, chew or crush KOSELUGO capsules.

•

KOSELUGO capsules may be administered with or without food.

KOSELUGO Oral Granules

Administer KOSELUGO oral granules to patients who have difficulty swallowing a whole capsule.

Sprinkle KOSELUGO oral granules on or mix with a small amount (about 1 to 3 teaspoons) of smooth yogurt, or fruit puree containing the following fruits: apple, banana, pear, or strawberry and consume within 30 minutes of preparation. If not consumed within 30 minutes of preparation, discard and prepare a new dose. If a dose has been partially consumed within 30 minutes of preparation, discard the remainder of the dose and do not prepare a new dose, aim to complete dosing within 30 minutes next time.

The KOSELUGO oral granules should be free-flowing. Do NOT use if the oral granules are clumped or stuck inside the capsule shell. Instruct the patient or caregiver to contact their pharmacy if this happens.

Discard the empty capsule shells after use.

Do NOT swallow, chew, or dissolve the capsule shells of KOSELUGO oral granules.

Do NOT chew or crush the KOSELUGO oral granules. Do NOT add oral granules to liquids.

Do NOT mix KOSELUGO oral granules in grapefruit or any juice, fruit puree or jam containing Seville orange. …

How to take Selumetinib — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Left Ventricular Dysfunction

Advise patients and caregivers that KOSELUGO can cause a reduction in LVEF and to immediately report any signs or symptoms of cardiomyopathy to their healthcare provider .

Ocular Toxicity

Advise patients and caregivers that KOSELUGO can cause ocular toxicity that can lead to blindness and to contact their healthcare provider if the patient experiences any changes in their vision .

Gastrointestinal Toxicity

Advise patients and caregivers that KOSELUGO can cause diarrhea, nausea, vomiting, and stomatitis and to contact their healthcare provider at the first sign of gastrointestinal toxicity .

Skin Toxicity

Advise patients and caregivers that KOSELUGO can cause serious skin toxicities and to contact their healthcare provider for severe skin changes .

Increased Creatine Phosphokinase

Advise patients and caregivers that KOSELUGO can cause increased CPK and rhabsomyolysis to report any signs and symptoms of muscle pain or weakness to their healthcare provider . …

Warnings & precautions

Do not take this medicine if: None.

KOSELUGO can cause cardiomyopathy, defined as a decrease in left ventricular ejection fraction (LVEF) ≥ 10% below baseline. KOSELUGO has not been studied in patients with a history of clinically significant cardiac disease or LVEF less than 55% prior to treatment.

Pediatric Patients

In the NF1 PN pediatric safety pool (N = 134) , Grade 2 LVEF decrease [Grade 2 LVEF decrease (40% to 50%; 10 to 19% drop from baseline)], based on reported adverse reactions, occurred in 17% of evaluable patients. Decreased LVEF of ≥ 20% occurred in 0.7% of patients and resulted in dose interruption and dose reduction. Decreased LVEF resolved in 75% of these patients. The median time to first onset of maximum CTCAE grade LVEF decrease was approximately 12 months (median duration approximately 3 months).

Adult Patients

In the KOMET adult NF1 PN study (N = 71) , Grade 2 LVEF decrease [Grade 2 LVEF decrease (40% to 50%; 10 to 19% drop from baseline)], based on echocardiogram results, occurred in 14% of evaluable patients. Decreased LVEF resulted in dose interruption in 1.4% of patients. The median time to first onset of maximum CTCAE grade LVEF decrease was approximately 4 months (median duration approximately 4 months).

Assess ejection fraction by echocardiogram prior to initiating treatment, every 3 months during the first year of treatment, every 6 months thereafter, and as clinically indicated. Withhold, reduce dose, or permanently discontinue KOSELUGO based on severity of adverse reaction . In patients who interrupt KOSELUGO for decreased LVEF, obtain an echocardiogram or a cardiac MRI every 3 to 6 weeks until resolution. Upon resolution of decreased LVEF to greater than or equal to the institutional LLN, obtain an echocardiogram or a cardiac MRI every 2 to 3 months or as directed by the cardiologist. …

Selumetinib side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

•Left Ventricular Dysfunction

•Ocular Toxicity

•Gastrointestinal Toxicity

•Skin Toxicity

•Increased Creatine Phosphokinase

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The NF1 PN pediatric safety pool described in the WARNINGS AND PRECAUTIONS reflects exposure to KOSELUGO at the recommended dosage in 134 pediatric patients in SPRINKLE (N = 36) (NCT05309668), SPRINT Phase I (N = 24) (NCT01362803), SPRINT Phase II Stratum 1 (N = 50) , and Phase I Food Effect Study (N = 24) (NCT05101148). Among pediatric patients, the duration of KOSELUGO exposure was 12 months or longer (80%), more than 2 years (44%), or more than 3 years (37%). The most common adverse reactions in pediatric patients (≥ 40%) are vomiting, diarrhea, increased creatine phosphokinase, dry skin, paronychia, nausea, dermatitis acneiform, and pyrexia.

In the KOMET adult NF1 PN study, 71 adult patients received KOSELUGO at the recommended dosage . Among adult patients, the duration of KOSELUGO exposure in the randomized period was 6 months or longer (92%), and 11 months or longer (66%). The most common adverse reactions in adult patients (≥ 40%) are rash (all), dermatitis acneiform, and diarrhea. …

Drug interactions

Strong or Moderate CYP3A4 Inhibitors or Fluconazole

Management | •Avoid concomitant use of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration with strong or moderate CYP3A4 inhibitors or fluconazole cannot be avoided, reduce KOSELUGO dosage .

Clinical Impact | •Concomitant use of KOSELUGO with a strong or moderate CYP3A4 inhibitor or fluconazole increased selumetinib plasma concentrations , which may increase the risk of adverse reactions.

Strong or Moderate CYP3A4 Inducers

Management | •Avoid concomitant use of strong or moderate CYP3A4 inducers with KOSELUGO.

Clinical Impact | •Concomitant use of KOSELUGO with a strong or moderate CYP3A4 inducer decreased selumetinib plasma concentrations , which may reduce KOSELUGO efficacy.

Vitamin E

Management | •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.

•Monitor for bleeding in patients administered a vitamin‑K antagonist or an anti‑platelet agent with KOSELUGO capsules. Increase INR monitoring, as appropriate, in patients taking a vitamin‑K antagonist . …

About this medicine

KOSELUGO contains selumetinib sulfate, a kinase inhibitor. The chemical name is 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-6-[(2-hydroxyethoxy)carbamoyl]-1-methyl-1H-benzimidazol-3-ium hydrogen sulfate. The molecular formula for selumetinib sulfate is C17H17BrClFN4O7S and the relative molecular mass is 555.76 g/mol. Selumetinib sulfate has the following structural formula:

Selumetinib sulfate is a white to yellow monomorphic crystalline powder that exhibits a pH dependent solubility. Selumetinib sulfate is freely soluble at pH < 1.5, sparingly soluble in the pH range at 1.5 to 3 and slightly soluble at pH > 3. Selumetinib sulfate has two ionizable functions with pKa values of 2.8 and 8.4.

KOSELUGO (selumetinib) 10 mg capsules for oral use, contain 10 mg selumetinib (equivalent to 12.1 mg selumetinib sulfate) and the excipient, vitamin E polyethylene glycol succinate. The capsule shell contains carnauba wax, carrageenan, hypromellose, potassium chloride, purified water, and titanium dioxide. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 7d042c61-f28f-4ab5-ab10-d7558c0d49ff. Read the full official label on DailyMed.